Key Findings on Deucravacitinib – A New Oral Treatment for Psoriasis

At EADV 2024, Dr. Melinda Gooderham presented key findings on deucravacitinib, a new oral treatment for psoriasis. Clinical trials (POETYK PSO-1/PSO-2) showed that more than half of patients improved significantly (PASI 75) by week 16, with sustained results for up to four years. The real-world evidence demonstrated significant reductions in psoriasis severity and improved quality of life after six months of treatment.